• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EDWARDS LIFESCIENCES CARPENTIER-EDWARDS PERIMOUNT MAGNA EASE PERICARDIAL BIOPROSTHESIS; REPLACEMENT HEART-VALVE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EDWARDS LIFESCIENCES CARPENTIER-EDWARDS PERIMOUNT MAGNA EASE PERICARDIAL BIOPROSTHESIS; REPLACEMENT HEART-VALVE Back to Search Results
Model Number 3300TFXJ
Device Problems Fluid/Blood Leak (1250); Gradient Increase (1270); Perivalvular Leak (1457); Patient Device Interaction Problem (4001); Device Stenosis (4066)
Patient Problem Insufficient Information (4580)
Event Type  Injury  
Manufacturer Narrative
The device was returned to edwards and is pending evaluation.The investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.Edwards will continue to review and monitor all events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
 
Event Description
It was reported that a patient with a 19mm 3300tfxj aortic pericardial valve was explanted after an implant duration of seven (7) years, one (1) month due to aortic stenosis and paravalvular leakage.The explanted valve was replaced with a 19mm 11500aj valve.Per the reported information, the patient was indicated for reoperation due to suspected aortic stenosis and regurgitation or paravalvular leakage.Preoperative echo could not distinguish between transvalvular regurgitation and paravalvular leakage.Upon the valve explant, the surgeon felt it was more likely to be paravalvular leakage.
 
Manufacturer Narrative
The device history record was reviewed and shows that this device met all manufacturing specifications for product release prior to distribution.No issues were identified that would have impacted this event.Regurgitation is considered to be a perivalvular leak (pvl) if a turbulent eccentric jet originates between the bioprosthetic sewing ring and the annulus.Pvl can occur in the mitral and aortic position for similar reasons.In the early postoperative period, the highest incidence of pvl has been seen in patients developing infective endocarditis, which is most likely attributed to inadequate peri-operative antibiotic prophylaxis or nosocomial infection.Annular calcification is also a risk factor for the development of peri-operative pvl as the bioprosthesis may not seat properly after debridement.Technique related factors, such as incorrect valve sizing, have been shown to contribute to the development of pvl.Anatomical factors may create difficulty seating the bioprosthetic valve resulting in pvl.The anatomy of the annulus may induce mechanical stresses along the rigid bioprosthetic ring which can influence long-term valve performance and durability.A diseased or rigid annulus can potentially increase the mechanical stress on the prosthetic valve, leading to pvl.Pannus overgrowth, or host tissue, is considered to be a form of non-structural valve dysfunction.The growth of host tissue on the sewing ring is expected and is a natural part of the healing reaction to prosthesis implantation.Pannus can have both beneficial and harmful effects depending on the amount of growth.A small amount of host tissue growth over the suture line is needed to form a non-thrombogenic surface and complete the healing process after valve implantation.In contrast, if there is an excessive amount of pannus growth, it can extend onto the cusp surfaces leading to thickening of the cusps, leaflet immobility, elevated gradients, and stenosis.Host tissue growth can also contribute to cusp retraction or curling resulting in valvular regurgitation.A definitive root cause cannot be conclusively determined; however, patient factors likely caused or contributed to the event.
 
Manufacturer Narrative
H3: customer report of paravalvular leakage was unable to be confirmed through visual observations.Report of stenosis was not confirmed.X-ray demonstrated wireform intact.Minimal host tissue overgrowth encroached onto the tissue and into the orifice at the greatest distance of approximately 2mm on leaflet 3 on the inflow aspect and 2mm on leaflet 2 on the outflow aspect.Host tissue on the stent circumference was moderate at the inflow aspect and minimal at the outflow aspect.Multiple suture holes were visible on the sewing ring.Updated sections: g3, g6, h2, h3, h6 device code(s), and type of investigation.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CARPENTIER-EDWARDS PERIMOUNT MAGNA EASE PERICARDIAL BIOPROSTHESIS
Type of Device
REPLACEMENT HEART-VALVE
Manufacturer (Section D)
EDWARDS LIFESCIENCES
one edwards way
irvine CA 92614
Manufacturer (Section G)
EDWARDS LIFESCIENCES
one edwards way
irvine CA 92614
Manufacturer Contact
saurav singh
1 edwards way
irvine, CA 92614
9492506615
MDR Report Key17248116
MDR Text Key318292412
Report Number2015691-2023-14341
Device Sequence Number1
Product Code DYE
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P860057/S042
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial,Followup,Followup
Report Date 08/31/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date06/12/2019
Device Model Number3300TFXJ
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer06/20/2023
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 06/05/2023
Initial Date FDA Received07/03/2023
Supplement Dates Manufacturer Received07/18/2023
08/15/2023
Supplement Dates FDA Received08/14/2023
08/30/2023
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured06/13/2015
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Life Threatening; Required Intervention;
Patient Age81 YR
Patient SexFemale
Patient Weight81 KG
-
-